2[1]Kannel WB, Abbott RD,Savage DD, et al. Epideminologic features of chronic atrial: the Framingham study[J]. N Engl J Med, 1982,306:1018- 1022
3[2]Benjamin EJ,Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham heart study[J ]. Circulation, 1998,98: 946 - 952
4[3]Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke and medical costs [ J ].Arch Intern Med, 1998,158: 229 - 234
5[4]Sopher SM, Camm AJ. Atrial fibrillation: maintenance of sinus rhythm versus rate control [ J ]. Am J Cardiol,1996,77: 24A- 37A
6[6]S Levy, G Breithardt, R W F. Campbell, at al. Atrial fibrillation: current knowledge and recommendations for management [J ]. Eur Heart J, 1998, 19:1294 -1320
7[7]Kreiss Y, Sidi Y, Gur H. Efficacy and safety of intravenous arniodarone in recent onset atria fibrillation:experience in patients admitted to a general internal medicine department [ J ]. Postgrad Med J, 1999, 75(2) :278 - 281
8[9]Reiffel JA. lntravenous amioxdarone in the management of atrial fibrillation[J ]. J Cardiovasc Pharmacol Ther,1999,4(4): 199 - 204
9[10]Bellandi F, Cantini F, Pedone T, et al. Effectiveness of lntravenous propafenone for conversion of recent - onset atrial fibrillation: a placebo - controlled study[J ].Clin Cardiol, 1995,18(11) :631 - 634
10[11]Fresco C, Proclemer A, Pavan A, et al. Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo - controlled, double - blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian trial(PAFIT) - 2 lnvestigators[J ]. Clin Cardiol, 1996, 19(5) :409 - 412
4Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA Guidelines for the management of patients with ST-elewttion myocardial infarction executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Re- vise the 1999 Guidelines for the Management of Patients with Acute My- ocardial Infarction ) [J]. Can J Cardiol, 2004Aug, 20 (10) : 977-1025.
5U jhely iMR,K lain erus KJ,Vad ieiK,et al. Disposition of intravenous amiodarone in subject swith normal and impaired renal function [J]. J Clin Pharma col, 1996,36 : 122-130.
